We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+15.33%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$112M
AUM Growth
-$4.51M
(-3.9%)
Cap. Flow
-$14.3M
Cap. Flow
% of AUM
-12.78%
Top 10 Holdings %
Top 10 Hldgs %
35.03%
Holding
122
New
10
Increased
13
Reduced
73
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QUMU
Qumu Corp.
QUMU
|
+$1.17M |
| 2 |
ASPU
ASPEN GROUP, INC.
ASPU
|
+$1.01M |
| 3 |
BIOL
Biolase, Inc.
BIOL
|
+$812K |
| 4 |
AKTS
Akoustis Technologies Inc
AKTS
|
+$759K |
| 5 |
FPAY
FlexShopper
FPAY
|
+$397K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTLP
Cantaloupe
CTLP
|
+$1.71M |
| 2 |
TEUM
Pareteum Corporation
TEUM
|
+$1.52M |
| 3 |
Apyx Medical
APYX
|
+$1.13M |
| 4 |
Natera
NTRA
|
+$995K |
| 5 |
Vericel Corp
VCEL
|
+$774K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.8% |
| 2 | Technology | 13.24% |
| 3 | Industrials | 6.62% |
| 4 | Communication Services | 6.04% |
| 5 | Consumer Staples | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NeoGenomics
NEO
$2.32B
| $7.39M | 6.62% |
252,500
-9,800
| -4% | -$233K |
|
|
2
Vericel Corp
VCEL
$2.1B
| $6.15M | 5.52% |
353,547
-45,450
| -11% | -$774K |
|
3
Axogen
AXGN
$2.77B
| $5.31M | 4.76% |
296,790
-22,985
| -7% | -$340K |
|
4
Veracyte
VCYT
$3.48B
| $3.7M | 3.32% |
132,630
-15,500
| -10% | -$401K |
|
5
Idexx Laboratories
IDXX
$43.7B
| $2.96M | 2.66% |
11,350
| – | – |
|
|
FPAY
6
DELISTED
FlexShopper
FPAY
| $2.87M | 2.57% |
1,132,400
+229,300
| +25% | +$397K |
|
|
CSII
7
DELISTED
Cardiovascular Systems, Inc.
CSII
| $2.86M | 2.56% |
58,783
-9,983
| -15% | -$455K |
|
|
8
Natera
NTRA
$47B
| $2.76M | 2.47% |
81,900
-27,000
| -25% | -$995K |
|
9
Microsoft
MSFT
$3.81T
| $2.58M | 2.32% |
16,385
| – | – |
|
10
Magnite
MGNI
$3.4B
| $2.5M | 2.24% |
305,733
-31,650
| -9% | -$260K |
|
11
Abbott
ABT
$195B
| $2.46M | 2.2% |
28,293
-6,318
| -18% | -$529K |
|
12
LeMaitre Vascular
LMAT
$1.84B
| $2.23M | 2% |
62,030
+900
| +1% | +$31.1K |
|
13
Exagen
XGN
$179M
| $2.18M | 1.96% |
85,850
-1,600
| -2% | -$28.5K |
|
14
Pfizer
PFE
$159B
| $2.04M | 1.83% |
54,956
-6,640
| -11% | -$237K |
|
15
Eli Lilly
LLY
$1.05T
| $1.85M | 1.66% |
14,100
-4,410
| -24% | -$511K |
|
16
Rockwell Medical
RMTI
$32.9M
| $1.81M | 1.63% |
6,758
-842
| -11% | -$212K |
|
17
Digital Turbine
APPS
$1.34B
| $1.8M | 1.62% |
252,800
-7,500
| -3% | -$55.8K |
|
|
HTGM
18
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
| $1.77M | 1.59% |
14,039
+966
| +7% | +$131K |
|
19
OptimizeRx
OPRX
$150M
| $1.77M | 1.59% |
172,172
-13,651
| -7% | -$155K |
|
20
CareDx
CDNA
$2.58B
| $1.75M | 1.57% |
81,133
-29,200
| -26% | -$670K |
|
21
CryoPort
CYRX
$815M
| $1.63M | 1.46% |
99,100
-3,500
| -3% | -$52.1K |
|
|
AKTS
22
DELISTED
Akoustis Technologies Inc
AKTS
| $1.63M | 1.46% |
203,500
+97,150
| +91% | +$759K |
|
23
AtriCure
ATRC
$2.47B
| $1.58M | 1.42% |
48,700
-6,300
| -11% | -$179K |
|
24
AT&T
T
$178B
| $1.57M | 1.4% |
53,042
-5,296
| -9% | -$153K |
|
25
Target
TGT
$74.1B
| $1.52M | 1.36% |
11,829
-2,811
| -19% | -$330K |
|
Similar funds
AA
WA
AC
BCVI
SWM
HAP
RHIG
CWM
Perkins Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Perkins Capital Management held 122 positions worth $112M, down 3.9% from $116M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Perkins Capital Management withdrew a net $14.3M in Q4 2019, closing 9 positions and reducing 73 holdings. Its most notable exit was Cantaloupe, an estimated $1.71M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 66% a quarter earlier, followed by Technology and Industrials.
Against the trend, Perkins Capital Management opened a new position in Qumu Corp. worth $1.11M.
- Perkins Capital Management's largest Q4 2019 buy was Qumu Corp.: 427,000 shares worth $1.11M.
- Perkins Capital Management added most to Akoustis Technologies Inc in Q4 2019, an estimated $759K increase.
- Perkins Capital Management's biggest Q4 2019 reduction was Apyx Medical, cutting an estimated $1.13M.
- Perkins Capital Management fully exited Cantaloupe in Q4 2019, selling an estimated $1.71M.
- Perkins Capital Management's ten largest holdings make up 35% of its $112M portfolio in Q4 2019.
- Perkins Capital Management opened 10 new positions and closed 9 in Q4 2019.
- Perkins Capital Management's portfolio value fell 3.9% quarter-over-quarter to $112M.
Based on Perkins Capital Management's 13F filing for Q4 2019, filed 3 Feb 2020.